| UniProt ID | BLMH_HUMAN | |
|---|---|---|
| UniProt AC | Q13867 | |
| Protein Name | Bleomycin hydrolase | |
| Gene Name | BLMH | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 455 | |
| Subcellular Localization | Cytoplasm. | |
| Protein Description | The normal physiological role of BLM hydrolase is unknown, but it catalyzes the inactivation of the antitumor drug BLM (a glycopeptide) by hydrolyzing the carboxamide bond of its B-aminoalaninamide moiety thus protecting normal and malignant cells from BLM toxicity.. | |
| Protein Sequence | MSSSGLNSEKVAALIQKLNSDPQFVLAQNVGTTHDLLDICLKRATVQRAQHVFQHAVPQEGKPITNQKSSGRCWIFSCLNVMRLPFMKKLNIEEFEFSQSYLFFWDKVERCYFFLSAFVDTAQRKEPEDGRLVQFLLMNPANDGGQWDMLVNIVEKYGVIPKKCFPESYTTEATRRMNDILNHKMREFCIRLRNLVHSGATKGEISATQDVMMEEIFRVVCICLGNPPETFTWEYRDKDKNYQKIGPITPLEFYREHVKPLFNMEDKICLVNDPRPQHKYNKLYTVEYLSNMVGGRKTLYNNQPIDFLKKMVAASIKDGEAVWFGCDVGKHFNSKLGLSDMNLYDHELVFGVSLKNMNKAERLTFGESLMTHAMTFTAVSEKDDQDGAFTKWRVENSWGEDHGHKGYLCMTDEWFSEYVYEVVVDRKHVPEEVLAVLEQEPIILPAWDPMGALAE | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 1 | Acetylation | -------MSSSGLNS -------CCCCCCCH | 8.71 | - | |
| 2 | Phosphorylation | ------MSSSGLNSE ------CCCCCCCHH | 32.96 | 19651622 | |
| 3 | Phosphorylation | -----MSSSGLNSEK -----CCCCCCCHHH | 27.42 | 19651622 | |
| 4 | Phosphorylation | ----MSSSGLNSEKV ----CCCCCCCHHHH | 39.74 | 18491316 | |
| 10 | Acetylation | SSGLNSEKVAALIQK CCCCCHHHHHHHHHH | 36.67 | 19608861 | |
| 10 | Ubiquitination | SSGLNSEKVAALIQK CCCCCHHHHHHHHHH | 36.67 | 23000965 | |
| 17 | Ubiquitination | KVAALIQKLNSDPQF HHHHHHHHHCCCCCE | 42.51 | 29967540 | |
| 42 | Ubiquitination | DLLDICLKRATVQRA HHHHHHHHHHHHHHH | 35.26 | 21963094 | |
| 42 | Acetylation | DLLDICLKRATVQRA HHHHHHHHHHHHHHH | 35.26 | 26051181 | |
| 45 | Phosphorylation | DICLKRATVQRAQHV HHHHHHHHHHHHHHH | 22.62 | 23532336 | |
| 58 | Phosphorylation | HVFQHAVPQEGKPIT HHHHHCCCCCCCCCC | 27.56 | 32645325 | |
| 62 | Ubiquitination | HAVPQEGKPITNQKS HCCCCCCCCCCCCCC | 32.28 | 21906983 | |
| 68 | Ubiquitination | GKPITNQKSSGRCWI CCCCCCCCCCCCEEE | 48.97 | 24816145 | |
| 184 | Acetylation | MNDILNHKMREFCIR HHHHHHHHHHHHHHH | 38.28 | 26822725 | |
| 184 | Ubiquitination | MNDILNHKMREFCIR HHHHHHHHHHHHHHH | 38.28 | 24816145 | |
| 202 | Ubiquitination | LVHSGATKGEISATQ HHHCCCCCCCCCCCH | 54.75 | 21963094 | |
| 238 | Ubiquitination | FTWEYRDKDKNYQKI CEEEEECCCCCCCCC | 62.70 | 23503661 | |
| 240 | Ubiquitination | WEYRDKDKNYQKIGP EEEECCCCCCCCCCC | 64.39 | 23503661 | |
| 244 | Ubiquitination | DKDKNYQKIGPITPL CCCCCCCCCCCCCHH | 38.99 | 21906983 | |
| 249 | Phosphorylation | YQKIGPITPLEFYRE CCCCCCCCHHHHHHH | 25.59 | - | |
| 259 | Acetylation | EFYREHVKPLFNMED HHHHHHCCCCCCCCC | 37.60 | 26822725 | |
| 259 | Ubiquitination | EFYREHVKPLFNMED HHHHHHCCCCCCCCC | 37.60 | 21906983 | |
| 267 | Ubiquitination | PLFNMEDKICLVNDP CCCCCCCCEEEECCC | 23.24 | 29967540 | |
| 279 | Ubiquitination | NDPRPQHKYNKLYTV CCCCCCCCCCCCHHH | 45.32 | 29967540 | |
| 279 | Acetylation | NDPRPQHKYNKLYTV CCCCCCCCCCCCHHH | 45.32 | 23749302 | |
| 280 | Phosphorylation | DPRPQHKYNKLYTVE CCCCCCCCCCCHHHH | 18.53 | - | |
| 282 | Ubiquitination | RPQHKYNKLYTVEYL CCCCCCCCCHHHHHH | 39.52 | 29967540 | |
| 282 | Acetylation | RPQHKYNKLYTVEYL CCCCCCCCCHHHHHH | 39.52 | 25953088 | |
| 284 | Phosphorylation | QHKYNKLYTVEYLSN CCCCCCCHHHHHHHH | 15.45 | - | |
| 288 | Phosphorylation | NKLYTVEYLSNMVGG CCCHHHHHHHHHCCC | 15.87 | - | |
| 297 | Ubiquitination | SNMVGGRKTLYNNQP HHHCCCCCCCCCCCC | 46.27 | 23000965 | |
| 300 | Phosphorylation | VGGRKTLYNNQPIDF CCCCCCCCCCCCHHH | 19.80 | 30576142 | |
| 309 | Ubiquitination | NQPIDFLKKMVAASI CCCHHHHHHHHHHHC | 38.52 | 21906983 | |
| 310 | Ubiquitination | QPIDFLKKMVAASIK CCHHHHHHHHHHHCC | 40.53 | 23503661 | |
| 317 | Ubiquitination | KMVAASIKDGEAVWF HHHHHHCCCCCEEEE | 58.13 | 29967540 | |
| 330 | Ubiquitination | WFGCDVGKHFNSKLG EEEEEEHHHHCCCCC | 44.89 | 29967540 | |
| 330 | Acetylation | WFGCDVGKHFNSKLG EEEEEEHHHHCCCCC | 44.89 | 25953088 | |
| 353 | Phosphorylation | HELVFGVSLKNMNKA CEEEEEEECCCCCHH | 33.72 | 24719451 | |
| 391 | Ubiquitination | DQDGAFTKWRVENSW CCCCCEEEEEEECCC | 26.92 | 19608861 | |
| 391 | Acetylation | DQDGAFTKWRVENSW CCCCCEEEEEEECCC | 26.92 | 19608861 | |
| 420 | Phosphorylation | EWFSEYVYEVVVDRK HHHHHHCCEEEECCC | 11.34 | 18083107 |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of BLMH_HUMAN !! | ||||||
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of BLMH_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of BLMH_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
| UBC9_HUMAN | UBE2I | physical | 9855622 | |
| KBTB7_HUMAN | KBTBD7 | physical | 16189514 | |
| BLMH_HUMAN | BLMH | physical | 16189514 | |
| TRIO_HUMAN | TRIO | physical | 16169070 | |
| A4_HUMAN | APP | physical | 10973933 | |
| RL11_HUMAN | RPL11 | physical | 10353821 | |
| RL29_HUMAN | RPL29 | physical | 10353821 | |
| BLMH_HUMAN | BLMH | physical | 21163940 | |
| TF2AA_HUMAN | GTF2A1 | physical | 22863883 | |
| LZTL1_HUMAN | LZTFL1 | physical | 22863883 | |
| PESC_HUMAN | PES1 | physical | 22863883 | |
| SHLB2_HUMAN | SH3GLB2 | physical | 22863883 | |
| BLMH_HUMAN | BLMH | physical | 25416956 | |
| NTAQ1_HUMAN | WDYHV1 | physical | 25416956 | |
| NUD12_HUMAN | NUDT12 | physical | 25416956 | |
| G6PD_HUMAN | G6PD | physical | 26344197 | |
| NUD12_HUMAN | NUDT12 | physical | 28514442 |
| Kegg Disease | |
|---|---|
| There are no disease associations of PTM sites. | |
| OMIM Disease | |
| There are no disease associations of PTM sites. | |
| Kegg Drug | |
| There are no disease associations of PTM sites. | |
| DrugBank | |
| DB00290 | Bleomycin |
loading...
| Acetylation | |
| Reference | PubMed |
| "Lysine acetylation targets protein complexes and co-regulates majorcellular functions."; Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.; Science 325:834-840(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-391, AND MASS SPECTROMETRY. | |